Asenapine: A review of its use in the management of mania in adults with bipolar i disorder

CNS Drugs

Volumn 25, Issue 3, 2011, Pages 251-267

  Chwieduk, Claudine M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Antipsychotics, general; Asenapine, general; Bipolar I disorders; Mania

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CIMETIDINE; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR; FLUVOXAMINE; HALOPERIDOL; HISTAMINE RECEPTOR; IMIPRAMINE; LITHIUM; LORAZEPAM; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; AMENORRHEA; ANXIETY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; BIPOLAR DISORDER; BIPOLAR MANIA; BLEPHAROSPASM; BRADYKINESIA; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE SEVERITY; DISTRIBUTION VOLUME; DIZZINESS; DOUBLE BLIND PROCEDURE; DOUBLE BLIND PROCEDURE (TOPIC); DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSKINESIA; DYSMENORRHEA; DYSPEPSIA; DYSTONIA; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FIRST PASS EFFECT; GAIT DISORDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERPROLACTINEMIA; INCREASED APPETITE; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL IRREGULARITY; METRORRHAGIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); MUSCLE RIGIDITY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PAIN; PARKINSONISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TARDIVE DYSKINESIA; TONGUE HYPESTHESIA; TOOTH PAIN; TORTICOLLIS; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; PSYCHIATRIC STATUS RATING SCALES;

EID: 79951794457     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11206700-000000000-00000     Document Type: Review

References (42)

1. Vieta E, Sanchez-Moreno J. Acute and long-term treat-ment of mania. Dialogues Clin Neurosci 2008; 10 (2): 165-79.
2. Grunze H, Vieta E, Goodwin GM, et al. The world federa-tion of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10 (2): 85-116.
3. Centorrino F, Mark TL, Talamo A, et al. Health and eco-nomic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol 2009; 29 (6): 595-600.
4. Chisholm D, van Ommeren M, Ayuso-Mateos J-L. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatr 2005; 187: 559-67. (Pubitemid 41752746)
5. National Collaborating Centre for Mental Health. Bipolar disorder: the management of bipolar disorder in adults, children, and adolescents, in primary and secondary care. Leicester: British Psychological Society, 2006: 592.
6. Revicki DA, Matza LS, Flood E, et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005; 23 (6): 583-94. (Pubitemid 40994126)
7. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009 Jan; 23 (1): 65-73.
8. Merck & Co. Saphris® (asenapine) sublingual tablets: US prescribing information [online]. Available from URL: http://www.spfiles.com/ pisaphrisv1.pdf[Accessed 2010 Sep 21].
9. European Medicines Agency. Summary of product char-acteristics [online]. Available from URL: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR- Product- Information/human/001177/WC500096895.pdf [Accessed 2010 Oct 1].
10. Weber J, McCormack PL. Asenapine. CNS Drugs 2009; 23 (9): 781-92.
11. 2 receptors in the rat brain. Eur Neuropsychopharmacol 2009 Mar; 19 (3): 177-87.
12. Tarazi FI, Moran-Gates T, Wong EH, et al. Asenapine in-duces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2010 Mar; 24 (3): 341-8.
13. Choi YK, Wong EH, Henry B, et al. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010 Apr; 13 (3): 405-10.
14. Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009 May; 63 (5): 413-20.
15. 2 receptor occupancy in rat brain [abstract no. 215]. 2nd Schizophrenia International Research Society Conference; 2010 Apr 10-14; Florence.
16. 2-receptor occupancy. Eur Psych 2007; 22 (5): 267-75. (Pubitemid 47096691)
17. Potkin SG, Alva G, Panagides J, et al. Predicting clinical antipsychotic doses from preclinical and PET studies: a case study with asenapine [abstract plus poster]. American College of Neuropsychopharmacology 42nd Annual Meeting; 2003 Dec 7-11; Puerto Rico.
18. 2 occupancy to predict efficacy and safety [abstract no. P.3.c.056]. Eur Neuropsychopharmacol 2008; 18 Suppl. 4: S436.
19. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebocontrolled trial. J Affect Disord 2010 Apr; 122 (1-2): 27-38.
20. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebocontrolled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009 Nov; 11 (7): 673-86.
21. McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010 Nov; 126 (3): 358-65.
22. Hulskotte E, Spaans E, Timmer C, et al. Effects of water intake and smoking on the absorption of sublingually administered asenapine [abstract no. PIII-57]. Clin Pharmacol Ther 2009; 85 Suppl. 1: S86.
23. Gerrits M, Doorstam DP, Spaans E, et al. Effect of valproate on the glucuronidation of asenapine [abstract no. PI-68]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S29.
24. Dogterom P, Hulskotte E, Gerrits M, et al. Asenapine pharma-cokinetics: influence of cytochrome P450 modulators and UDP-glucuronyltransferase inhibition [abstract no. P.3.d.008]. Eur Neuropsychopharmacol 2008 Aug; 18 Suppl. 4: S452-3.
25. Dogterom P, Schnabel PG, Timmer C, et al. Effect of car-bamazepine on asenapine pharmacokinetics [abstract no. PII-44]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S55.
26. Peeters PA, Bockbrader H, Spaans E, et al. Impaired renal function has little or no effect on asenapine pharmaco-kinetics [abstract no. PI-49]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S23.
27. Peeters PA, Bockbrader H, Spaans E, et al. Influence of hepatic impairment on asenapine pharmacokinetics [abstract no. PI-48]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S23.
28. Calabrese J, Stet L, Kotari H, et al. Asenapine as adjunctive treatment for bipolar mania: results of a placebocontrolled 12-week study and 40-week extension [abstract no. PW01-28]. Eur Psychiatry 2010; 25 Suppl. 1: 1447.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
30. McIntyre RS, Cohen M, Zhao J, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009 Dec; 11 (8): 815-26.
31. Calabrese JR, Cohen M, Zhao J, et al. Efficacy and safety of asenapine adjunctive treatment for acute mania associated with bipolar disorder [abstract no. NR3-061]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC.
32. Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009; 49 (11): 1297-308.
33. Hirschfield RMA. Guideline watch: practice guideline for the treatment of patients with bipolar disorder, second edition [online]. Available from URL: http://www.psy chiatryonline.com/pracGuide/PracticePDFs/Bipolar.watch.pdf [Accessed 2010 Aug 26].
34. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008; 11 (7): 999-1029.
35. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009; 63 (12): 1762-84.
36. McIntyre RS. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev Neurother 2010; 10 (5): 645-9.
37. Ortho-McNeil-Janssen Pharmaceuticals. Risperdal (risper-idone) tablets/oral solution: US prescribing information [online]. Available from URL: http://www.risperdal.com/sites/default/files/shared/pi/risperdal.pdf [Accessed 2010 Nov 10].
38. Ortho-McNeil-Janssen Pharmaceuticals. Invega (paliper-idone) extended-release tablets: US prescribing information [online]. Available from URL: http://www.invega. com/invega/shared/pi/invega.pdf#zoom=100 [Accessed 2010 Nov 10].
39. 2C serotonin receptors. Nature 1995 Apr; 374: 542-6.
40. Schering-Plough. A study to evaluate the safety and toler-ability of sublingual asenapine in a pediatric population with schizophrenia or bipolar I disorder (study p06522) [ClinicalTrials.gov identifier NCT01206517]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 30].
41. Schering-Plough. Evaluating the safety and efficacy of ase-napine in subjects with bipolar 1 acute manic or mixed episode (study 41044) (P05691AM1) [ClinicalTrials.gov identifier NCT00764478]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 30]
42. Schering-Plough. Study of asenapine in elderly subjects with psychosis A7501021) (P05717) (COMPLETED) [Clinical-Trials.gov identifier NCT00281320]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 30]